BCLI

Brainstorm Cell Therapeutics Inc. (BCLI) is a pioneering biotechnology company dedicated to the advancement of innovative autologous cell therapies targeting neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS). Headquartered in New York, BCLI's lead product, NurOwn, leverages a proprietary stem cell technology platform designed to utilize patients' own cells for therapeutic benefits, with the potential to slow disease progression and improve patients' quality of life. With a robust focus on scientific research and development, Brainstorm aims to establish itself as a frontrunner in the evolving fields of cellular therapy and neurology, offering renewed hope to patients and their families confronting these debilitating diseases.